Treatment and prognostic factors in primary peritoneal carcinoma: A multicenter study of the anatolian society of medical oncology (ASMO)

Basit Öğe Kaydı
dc.contributor.authorÜnal, Olçun Ümit
dc.contributor.authorÖztop, İlhan
dc.contributor.authorYazıcı, Ozan
dc.contributor.authorÖzatlı, Tahsin
dc.contributor.authorİnal, Ali
dc.contributor.authorGünaydin, Yusuf
dc.contributor.authorAlıcı, Süleyman
dc.date.accessioned2024-04-24T17:56:31Z
dc.date.available2024-04-24T17:56:31Z
dc.date.issued2014
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Onkoloji Ana Bilim Dalıen_US
dc.description.abstractBackground: In this study, we aimed to evaluate the clinicopathological characteristics and prognosis of patients with primary peritoneal carcinoma (PPC), and the effectiveness and toxicity of first-line platinum/taxane combination therapy. Patients and Methods: We retrospectively evaluated 79 patients with PPC, who were treated and followed up between December 2001 and August 2012 at 10 medical oncology clinics. Results: All patients were female, with a median age of 63 years (range 34-79 years). Histopathological diagnoses included primary peritoneal serous carcinoma (PPSC) (n = 69) and mixed epithelial carcinoma of the peritoneum (MEC) (n = 10). Patients received first-line treatment with carboplatin/paclitaxel (n = 67) or cisplatin/paclitaxel (n = 12) combination therapy. Overall response rate, median progression-free survival, and median survival time in the paclitaxel/ carboplatin group and the paclitaxel/cisplatin group were 74.6 vs. 75%, 15.6 vs. 37.8 months, and 41 vs. 70.3 months, respectively. In multivariate analysis, favorable prognostic factors were: ECOG performance status 0 (p < 0.001) and optimal cytoreduction (p = 0.03). Conclusion: PPC is a rare, heterogeneous disease. ECOG performance status and optimal cytoreduction are important prognostic factors regarding survival rates. Platinum/taxane combination therapy is an effective and tolerable regimen in this patient group.en_US
dc.identifier.citationÜnal, O. Ü., Öztop, İ., Yazıcı, O., Özatlı, T., İnal, A., Günaydin, Y. ve diğerleri. (2014). Treatment and prognostic factors in primary peritoneal carcinoma: A multicenter study of the anatolian society of medical oncology (ASMO). Oncology Research and Treatment, 37(6), 332-338.
dc.identifier.doi10.1159/000362857
dc.identifier.endpage338en_US
dc.identifier.issn2296-5270
dc.identifier.issue6en_US
dc.identifier.pmid24903764
dc.identifier.scopus2-s2.0-84902246479
dc.identifier.scopusqualityQ3
dc.identifier.startpage332en_US
dc.identifier.urihttps://doi.org/10.1159/000362857
dc.identifier.urihttps://hdl.handle.net/11468/23552
dc.identifier.volume37en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherS. Karger AGen_US
dc.relation.ispartofOncology Research and Treatment
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCarboplatinen_US
dc.subjectChemotherapyen_US
dc.subjectPaclitaxelen_US
dc.subjectPrognostic factoren_US
dc.titleTreatment and prognostic factors in primary peritoneal carcinoma: A multicenter study of the anatolian society of medical oncology (ASMO)en_US
dc.titleTreatment and prognostic factors in primary peritoneal carcinoma: A multicenter study of the anatolian society of medical oncology (ASMO)
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu